Navitoclax-d8

Navitoclax-d8 is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].

Product Specifications

CAS Number

[1217620-38-6]

UNSPSC

12352005

Target

Bcl-2 Family

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis

Field of Research

Cancer

Purity

99.71

Solubility

10 mM in DMSO|DMSO : ≥ 25mg/mL

Smiles

CC(C)(C1)CCC(C2=CC=C(C=C2)Cl)=C1CN3CCN(C4=CC=C(C=C4)C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(C=C5)N[C@@H](CSC6=CC=CC=C6)CCN7C([2H])([2H])C([2H])([2H])OC([2H])([2H])C7([2H])[2H])=O)=O)CC3

Molecular Formula

C47H47D8ClF3N5O6S3

Molecular Weight

982.66

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Chen J, et al. The Bcl-2/Bcl-X (L) /Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10 (12) :2340-9.|[3]Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50 (6) :1181-1189.|[4]Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x (L) -mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11 (4) :1026-1035.